Joint (JYNT)
Market Price (12/4/2025): $8.5 | Market Cap: $130.4 MilSector: Health Care | Industry: Health Care Facilities
Joint (JYNT)
Market Price (12/4/2025): $8.5Market Cap: $130.4 MilSector: Health CareIndustry: Health Care Facilities
Investment Highlights
Why It Matters
Which of these 2 stories sounds closer for this stock?
1. Generates cash flow
The stock generated 4% or more of the share price (called cash flow yield), and shows moderate 10-15% or more growth.
2. Riding a trend
Think Tesla during the pandemic of 2020 when EVs were riding a cultural high, or Nvidia in the current AI boom, or even Figma. These companies don’t have enough yield, or, enough growth, or both - however - they are riding a trend. They have momentum. These can be more volatile - they don’t have the floor of strong cash flow
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -19% | Weak multi-year price returns2Y Excs Rtn is -59%, 3Y Excs Rtn is -115% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -0.8 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -1.4% |
| Strong revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is 2150% | Expensive valuation multiplesP/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 48x, P/EPrice/Earnings or Price/(Net Income) is 76x | |
| Low stock price volatilityVol 12M is 42% | Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -2.8% | |
| Megatrend and thematic driversMegatrends include Aging Population & Chronic Disease, and Health & Wellness Trends. Themes include Geriatric Care, Preventative Healthcare, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -19% |
| Strong revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is 2150% |
| Low stock price volatilityVol 12M is 42% |
| Megatrend and thematic driversMegatrends include Aging Population & Chronic Disease, and Health & Wellness Trends. Themes include Geriatric Care, Preventative Healthcare, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -59%, 3Y Excs Rtn is -115% |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -0.8 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -1.4% |
| Expensive valuation multiplesP/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 48x, P/EPrice/Earnings or Price/(Net Income) is 76x |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -2.8% |
Valuation, Metrics & Events
JYNT Stock
Why The Stock Moved
Qualitative Assessment
AI Generated Analysis | Feedback
Here are the key points explaining why Joint (symbol: JYNT) stock moved by -22% for the approximate time period from August 31, 2025, to December 4, 2025:
1. Q3 2025 Earnings Report Triggers Significant Stock Plunge.
On November 6, 2025, The Joint Corp. released its third-quarter 2025 financial results. Despite reporting earnings per share (EPS) and revenue that surpassed analyst estimates, the stock experienced a substantial decline, plummeting by 34.25% in after-hours trading.
2. Downward Revision of Full-Year Sales and Comparable Store Sales Guidance.
Following the Q3 earnings, the company revised its 2025 system-wide sales guidance downward to a range of $530-$534 million. Additionally, it adjusted its comparable sales growth expectation to between -1% and 0%, a decrease from previous guidance of low-single-digit growth, signaling a more cautious outlook on future performance.
Stock Movement Drivers
Return vs. Risk
Price Returns Compared
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| JYNT Return | 63% | 150% | -79% | -31% | 11% | -22% | -49% |
| Peers Return | -2% | 73% | -2% | -3% | 4% | 5% | 77% |
| S&P 500 Return | 16% | 27% | -19% | 24% | 23% | 16% | 112% |
Monthly Win Rates [3] | |||||||
| JYNT Win Rate | 67% | 58% | 25% | 33% | 58% | 50% | |
| Peers Win Rate | 52% | 77% | 48% | 52% | 44% | 45% | |
| S&P 500 Win Rate | 58% | 75% | 42% | 67% | 75% | 70% | |
Max Drawdowns [4] | |||||||
| JYNT Max Drawdown | -50% | 0% | -80% | -47% | -7% | -28% | |
| Peers Max Drawdown | -46% | -2% | -27% | -25% | -28% | -23% | |
| S&P 500 Max Drawdown | -31% | -1% | -25% | -1% | -2% | -15% | |
[1] Cumulative total returns since the beginning of 2020
[2] Peers: MGRC, CRAI, III, TBI, AMTU. See JYNT Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2025 data is for the year up to 12/3/2025 (YTD)
How Low Can It Go
| Event | JYNT | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -93.1% | -25.4% |
| % Gain to Breakeven | 1355.9% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -52.9% | -33.9% |
| % Gain to Breakeven | 112.5% | 51.3% |
| Time to Breakeven | 149 days | 148 days |
| 2018 Correction | ||
| % Loss | -31.5% | -19.8% |
| % Gain to Breakeven | 45.9% | 24.7% |
| Time to Breakeven | 162 days | 120 days |
Compare to MGRC, CRAI, III, TBI, AMTU
In The Past
Joint's stock fell -93.1% during the 2022 Inflation Shock from a high on 9/3/2021. A -93.1% loss requires a 1355.9% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth over time.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
Latest Trefis Analyses
| Title | |
|---|---|
| ARTICLES |
Trade Ideas
Select past ideas related to JYNT. For more, see Trefis Trade Ideas.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 11142025 | CRL | Charles River Laboratories International | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 4.1% | 4.1% | -3.7% |
| 11142025 | GDRX | GoodRx | Dip Buy | DB | CFO/Rev | Low D/EDip Buy with High Cash Flow MarginsBuying dips for companies with significant cash flows from operations and reasonable debt / market cap | -9.8% | -9.8% | -11.8% |
| 11142025 | ASTH | Astrana Health | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 6.0% | 6.0% | -5.5% |
| 11142025 | SGRY | Surgery Partners | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 9.7% | 9.7% | -1.4% |
| 11072025 | TFX | Teleflex | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 6.2% | 6.2% | -5.1% |
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 11142025 | CRL | Charles River Laboratories International | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 4.1% | 4.1% | -3.7% |
| 11142025 | GDRX | GoodRx | Dip Buy | DB | CFO/Rev | Low D/EDip Buy with High Cash Flow MarginsBuying dips for companies with significant cash flows from operations and reasonable debt / market cap | -9.8% | -9.8% | -11.8% |
| 11142025 | ASTH | Astrana Health | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 6.0% | 6.0% | -5.5% |
| 11142025 | SGRY | Surgery Partners | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 9.7% | 9.7% | -1.4% |
| 11072025 | TFX | Teleflex | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 6.2% | 6.2% | -5.1% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons for Joint
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 8.38 |
| Mkt Cap | 0.3 |
| Rev LTM | 731 |
| Op Inc LTM | 13 |
| FCF LTM | 27 |
| FCF 3Y Avg | 6 |
| CFO LTM | 31 |
| CFO 3Y Avg | 21 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 4.8% |
| Rev Chg 3Y Avg | 8.0% |
| Rev Chg Q | 5.7% |
| QoQ Delta Rev Chg LTM | 1.4% |
| Op Mgn LTM | 5.3% |
| Op Mgn 3Y Avg | 7.5% |
| QoQ Delta Op Mgn LTM | 0.1% |
| CFO/Rev LTM | 5.7% |
| CFO/Rev 3Y Avg | 7.5% |
| FCF/Rev LTM | 3.9% |
| FCF/Rev 3Y Avg | 2.8% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 0.3 |
| P/S | 1.9 |
| P/EBIT | 12.5 |
| P/E | 24.2 |
| P/CFO | 13.6 |
| Total Yield | 5.1% |
| Dividend Yield | 1.0% |
| FCF Yield 3Y Avg | 4.1% |
| D/E | 0.2 |
| Net D/E | 0.1 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | -2.2% |
| 3M Rtn | -9.6% |
| 6M Rtn | -7.6% |
| 12M Rtn | -12.5% |
| 3Y Rtn | 10.9% |
| 1M Excs Rtn | -2.1% |
| 3M Excs Rtn | -15.4% |
| 6M Excs Rtn | -22.4% |
| 12M Excs Rtn | -26.4% |
| 3Y Excs Rtn | -58.5% |
Returns Analyses
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 9302025 | 11072025 | 10-Q 9/30/2025 |
| 6302025 | 8122025 | 10-Q 6/30/2025 |
| 3312025 | 5092025 | 10-Q 3/31/2025 |
| 12312024 | 3142025 | 10-K 12/31/2024 |
| 9302024 | 11082024 | 10-Q 9/30/2024 |
| 6302024 | 8092024 | 10-Q 6/30/2024 |
| 3312024 | 5032024 | 10-Q 3/31/2024 |
| 12312023 | 3082024 | 10-K 12/31/2023 |
| 9302023 | 11132023 | 10-Q 9/30/2023 |
| 6302023 | 9262023 | 10-Q 6/30/2023 |
| 3312023 | 5052023 | 10-Q 3/31/2023 |
| 12312022 | 3102023 | 10-K 12/31/2022 |
| 9302022 | 11042022 | 10-Q 9/30/2022 |
| 6302022 | 8052022 | 10-Q 6/30/2022 |
| 3312022 | 5062022 | 10-Q 3/31/2022 |
| 12312021 | 3142022 | 10-K 12/31/2021 |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |